Semaglutide
Semaglutide is one of the most widely studied weight-loss and diabetes drugs in the world.
We have not published an audit on Semaglutide. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Semaglutide is a GLP-1 receptor agonist that copies a natural gut hormone (GLP-1) that helps the body manage hunger and blood sugar. [Source: Peptide Dosing Protocols]
Semaglutide mimics a natural gut hormone (GLP-1) to reduce hunger, slow digestion, help control blood sugar, and protect the heart, all by activating the GLP-1 receptor in multiple organs throughout the body.
Reported side effects
The most common side effects are nausea, diarrhea, vomiting, and constipation, which are usually worst during the first few months of dose escalation and tend to improve over time.
Who should avoid it
People with a personal or family history of medullary thyroid cancer or MEN 2, known allergy to semaglutide, or certain conditions like severe gastroparesis, pancreatitis history, or active pregnancy should avoid semaglutide or use it only under close medical supervision.
What gets monitored
Body weight and HbA1c at weeks 1-4, 5-8, 8-12, 16-20, 28, and 68. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Semaglutide or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 2.4 mg · Low: 0.25 mg · High: 2.4 mg | once weekly16 weeks · 16 weeks on, ongoing weekly maintenance | subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: about 7 days. Standard dosing escalates to 2.4 mg over 16 weeks. |
- once weekly16 weeks · 16 weeks on, ongoing weekly maintenance
- subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Half-life: about 7 days. Standard dosing escalates to 2.4 mg over 16 weeks.
- reconstituted lyophilized vial
Common questions
What is the starting dose of semaglutide?
The FDA-approved starting dose for weight management (Wegovy) is 0.25 mg once weekly by subcutaneous injection.
What is semaglutide's half-life?
Semaglutide has a half-life of about 7 days.
How much weight can you lose on semaglutide?
In the STEP 1 clinical trial, participants on semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks.
How do you reconstitute semaglutide?
A common setup is a 5 mg vial with 2.0 mL bacteriostatic water.
Check 5 mg in 2 mL in the calculator →Is semaglutide FDA-approved?
Yes, as of June 2026, semaglutide has broad FDA approval across multiple indications.
What are the most common side effects?
Stomach side effects are most common, including nausea, diarrhea, vomiting, and constipation.
Sources
The reference sections above are imported from our compound knowledge base, which classes the evidence for Semaglutide as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
Blend of cagrilintide (amylin analog) and retatrutide (triple GLP-1/GIP/glucagon agonist), studied for weight management.
Blend of cagrilintide (amylin analog) and tirzepatide (GIP/GLP-1 dual agonist), studied for weight management.
Investigational fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), studied once weekly for weight management.
Investigational GLP-1 and glucagon receptor dual agonist studied for weight management and metabolic health.
Investigational triple GLP-1 / GIP / glucagon receptor agonist studied for weight management.
Dual GIP and GLP-1 receptor agonist studied for weight management and glycemic control.